Our drug development program includes different indications and formulations to address one of the biggest medical challenges of our time: a way to restore the impairment of cognitive functions in the brain or, at least, to stop the progression of neurodegenerative disease.
Our drug development program includes different indications and formulations to address one of the biggest medical challenges of our time: a way to restore the impairment of cognitive functions in the brain or, at least, to stop the progression of neurodegenerative disease.
Pipeline
In addition to the most prevalent cause of dementia, AD, there are other potential indications of ONESTX-1 as Parkinson disease (PD) or Huntington disease (HD). The action of ONESTX-1 might be further improved with the combination with specific sulphated neurosteroid hormones as DHEA-S.
| Commercial product | Drug Substance | Development | Application |
|---|---|---|---|
| ONESTX-1 | STX64 | Phase I | Alzheimer’s disease |
| ONESTX-1 | STX64 | Preclinical*, Phase I | Huntington’s disease |
| ONESTX-1 | STX64 | Preclinical*, Phase I | Parkinson’s disease |
| ONESTX-1 | STX64 | Preclinical*, Phase I | Age-related cognitive impairment |
| ONESTX-1 | STX64+NS** | Preclinical*, Phase I | Neurodegeneration |
*Data only in animal worm models.
**NS: Neurosteroids, sulfated steroids.